WebFeb 24, 2024 · This first-in-human study will evaluate the recommended dose for further clinical development, safety, tolerability, anti-tumor activity, immunogenicity, … WebThis is an open-label study of INCB047986 given to two distinct groups of patients (Group 1 and Group 2) with advanced malignancies. The purpose of the study is to evaluate the safety, tolerability and pharmacokinetics of INCB047986 and to determine the maximum tolerated dose of INCB047986 in combination with gemcitabine and nab paclitaxel in a …
An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in
WebOn Day 1, subjects will be randomized to 1 of 4 dose groups of 15 subjects each (INCB047986 4 mg, 8 mg, 12 mg, or placebo QD). Study drug will be self administered on Days 1 through 28. A follow-up telephone call to the subject to assess safety will occur at Day 42. A final safety and efficacy evaluation will be performed at the Day 58 visit. WebThis is an open-label study of INCB047986 given to two distinct groups of patients (Group 1 and Group 2) with advanced malignancies. The purpose of the study is to evaluate the safety, tolerability and pharmacokinetics of INCB047986 and to determine the maximum tolerated dose of INCB047986 in combination with gemcitabine and nab paclitaxel in a … earring lock backs
API incb047986 - Long Island University
WebThis trial was about to investigate the efficacy and safety of three dose levels of INCB047986 [Incyte Corporation] in patients with myelodysplastic syndrome A … WebEnsaios clínicos em tumore solido avanzato con evidenza di linea germinale o brca somatica. Registro de ensaios clínicos. ICH GCP. Webincb047986 incb-047986 incb-47986 Organizations (1) Research & Development (1) Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort; Marketing (0) Organization Org Type FDA approvals … earring lock